Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia Thomas, S. K., Harb, W. A., Beck, J., Nashat, G., Palomba, M., Ansell, S. M., Eradat, H., Libby, E. N., Advani, R. H., Hajdenberg, J., Heffner, L. T., Hoffman, J., Vesole, D. H., Simov, L., Wyant, N., Brevard, J., O'Leary, J., Agrawal, S. AMER SOC HEMATOLOGY. 2015

View details for Web of Science ID 000368019005018